Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...

Novo Nordisk CEO Lars Fruergaard Jorgensen has called attention to the complexities of the U.S. healthcare system while ...

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.

Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...

The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...

The retrospective study points to fewer suicidal thoughts or attempts among adolescents taking semaglutide or liraglutide.

President Biden and Sen. Bernie Sanders (I-Vt.) will travel to New Hampshire on Tuesday to speak on health care savings ...